Why Eurofins Scientific (ENXTPA:ERF) is back on investor radars Eurofins Scientific (ENXTPA:ERF) has drawn fresh attention after cancelling 6,163,000 previously repurchased shares, trimming its share ...

Eurofins Scientific SE (the "Company" or "Eurofins") (EUFI.PA) (Paris:ERF) announces that its Board of Directors has decided on the cancellation of 6,163,000 shares, representing 3.38% of the ...

Eurofins Lancaster Laboratories plans to break ground this spring on a $147 million expansion that will add biopharmaceutical testing labs and office space.

Eurofins Supplement Testing and the Eurofins Assurance network are pleased to announce that their Certified Dietary ...

Eurofins Viracor, a leader in advanced clinical diagnostics, today announced the launch of the ExPeCT™ anti-CD19 (obe-cel) CAR T-cell assay, a cutting-edge solution designed to help clinicians monitor ...

Eurofins has a repurchase program that contemplates buying back up to 4.5% of its share capital from April 2025 to April 2026. The company expects that its revenues will grow by approximately 8.6% ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Shares in French diagnostic and testing group Eurofins tumbled as much as 23 per cent on Monday after hedge ...

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins (Paris:ERF): Eurofins Scientific (EUFI.PA), a European leader in Forensic DNA and Toxicology testing in France, Germany and Belgium, announces ...